Comparative effectiveness review of treatment options for pituitary microadenomas in acromegaly: Clinical article

Journal of Neurosurgery

Volumn 117, Issue 3, 2012, Pages 522-538

  Marko, Nicholas F ^a   Lasota, Emily ^b   Hamrahian, Amir H ^a   Weil, Robert J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acromegaly; Comparative effectiveness research; Cost; Efficacy; Microadenoma; Pituitary adenoma; Pituitary surgery; Quality of life

Indexed keywords

ANGIOPEPTIN; OCTREOTIDE; PEGVISOMANT;

ABDOMINAL PAIN; ACROMEGALY; ARTICLE; CHOLELITHIASIS; COMPARATIVE EFFECTIVENESS; COST BENEFIT ANALYSIS; DECISION TREE; DIARRHEA; DRUG COST; DRUG EFFICACY; HAIR LOSS; HUMAN; HYPOPHYSIS ADENOMA; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SIDE EFFECT; STEREOTACTIC RADIOSURGERY; THERAPY EFFECT; TRANSSPHENOIDAL SURGERY; TREATMENT OUTCOME;

ADENOMA; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DISEASE MANAGEMENT; DRUG THERAPY; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; NEUROSURGICAL PROCEDURES; PITUITARY NEOPLASMS; QUALITY OF LIFE; RADIOSURGERY; RADIOTHERAPY; TREATMENT OUTCOME;

EID: 84865844655     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2012.4.JNS11739     Document Type: Article

References (89)

1. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB: Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 83:3411-3418, 1998 (Pubitemid 28500865)
2. Attanasio R, Epaminonda P, Motti E, Giugni E, Ventrella L, Cozzi R, et al: Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. J Clin Endocrinol Metab 88:3105- 3112, 2003
3. Badia X, Webb SM, Prieto L, Lara N: Acromegaly Quality of Life Questionnaire (AcroQoL). Health Qual Life Outcomes 2:13, 2004
4. Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF, et al: Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 82:3187-3191, 1997 (Pubitemid 27419054)
5. Barrande G, Pittino-Lungo M, Coste J, Ponvert D, Bertagna X, Luton JP, et al: Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab 85:3779-3785, 2000
6. Bates PR, Carson MN, Trainer PJ, Wass JA: Wide variation in surgical outcomes for acromegaly in the UK. Clin Endocrinol (Oxf) 68:136-142, 2008 (Pubitemid 350243493)
7. Beauregard C, Truong U, Hardy J, Serri O: Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 58:86-91, 2003 (Pubitemid 36098853)
8. Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S, Melmed S: Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 14:284-294, 2011
9. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, et al: Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 87:4554-4563, 2002
10. Biermasz NR, Roelfsema F, Pereira AM, Romijn JA: Costeffectiveness of lanreotide Autogel in treatment algorithms of acromegaly. Expert Rev Pharmacoecon Outcomes Res 9:223-234, 2009
11. Biermasz NR, van Dulken H, Roelfsema F: Long-term followup results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab 85:2476-2482, 2000 (Pubitemid 32269203)
12. Biermasz NR, van Dulken H, Roelfsema F: Ten-year followup results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab 85:4596-4602, 2000 (Pubitemid 32157639)
13. Biermasz NR, van Thiel SW, Pereira AM, Hoftijzer HC, van Hemert AM, Smit JW, et al: Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab 89:5369-5376, 2004 (Pubitemid 39518410)
14. Buchfelder M, Schlaffer S: Surgical treatment of pituitary tumours. Best Pract Res Clin Endocrinol Metab 23:677-692, 2009
15. Buchfelder M, Weigel D, Droste M, Mann K, Saller B, Brübach K, et al: Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Eur J Endocrinol 161:27-35, 2009
16. Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Laurberg P, et al: Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 87:99-104, 2002 (Pubitemid 34084677)
17. Caron P, Bex M, Cullen DR, Feldt-Rasmussen U, Pico Alfonso AM, Pynka S, et al: One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol (Oxf) 60:734-740, 2004 (Pubitemid 38788082)
18. Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn JM: Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf) 64:209-214, 2006
19. Castinetti F, Morange I, Dufour H, Regis J, Brue T: Radiotherapy and radiosurgery in acromegaly. Pituitary 12:3-10, 2009
20. Castinetti F, Régis J, Dufour H, Brue T: Role of stereotactic radiosurgery in the management of pituitary adenomas. Nat Rev Endocrinol 6:214-223, 2010
21. Castinetti F, Taieb D, Kuhn JM, Chanson P, Tamura M, Jaquet P, et al: Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab 90:4483-4488, 2005 (Pubitemid 41159330)
22. Chanson P, Boerlin V, Ajzenberg C, Bachelot Y, Benito P, Bringer J, et al: Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf) 53:577-586, 2000
23. Chanson P, Borson-Chazot F, Kuhn JM, Blumberg J, Maisonobe P, Delemer B: Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf) 69:299-305, 2008 (Pubitemid 352009031)
24. Chanson P, Salenave S, Kamenicky P, Cazabat L, Young J: Pituitary tumours: acromegaly. Best Pract Res Clin Endocrinol Metab 23:555-574, 2009
25. Colao A: The importance of presurgical somatostatin analogue therapy in acromegaly. Endokrynol Pol 58:356-360, 2007
26. Colao A, Auriemma RS, Lombardi G, Pivonello R: Resistance to somatostatin analogs in acromegaly. Endocr Rev 32:247-271, 2011
27. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, et al: Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86:2779-2786, 2001 (Pubitemid 32545739)
28. Cozzi R, Barausse M, Asnaghi D, Dallabonzana D, Lodrini S, Attanasio R: Failure of radiotherapy in acromegaly. Eur J Endocrinol 145:717-726, 2001 (Pubitemid 33133678)
29. Cozzi R, Dallabonzana D, Attanasio R, Barausse M, Oppizzi G: A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. Eur J Endocrinol 141:267-271, 1999 (Pubitemid 29465932)
30. De P, Rees DA, Davies N, John R, Neal J, Mills RG, et al: Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission. J Clin Endocrinol Metab 88:3567-3572, 2003 (Pubitemid 37034496)
31. Fallon Community Health Plan: Lanreotide (Somatuline Depot). Prior Authorization Approval Criteria. Worcester, MA: Fallon Community Health Plan, 2008 (http://www.fchp.org/~/media/Files/FCHP/Imported/SomatulineDepot- lanreotide.pdf.ashx) [Accessed April 25, 2012]
32. Fallon Community Health Plan: Octreotide (Sandostatin). Prior Authorization Approval Criteria. Worcester, MA: Fallon Community Health Plan, 2008 (http://www.fchp.org/~/media/Files/FCHP/Imported/Sandostatin-octreotide. pdf. ashx) [Accessed April 25, 2012]
33. Feelders RA, Hofland LJ, van Aken MO, Neggers SJ, Lamberts SW, de Herder WW, et al: Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs 69:2207-2226, 2009
34. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, et al: Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365:1644-1646, 2005 (Pubitemid 40693415)
35. Freda PU, Wardlaw SL, Post KD: Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 89:353-358, 1998 (Pubitemid 28405246)
36. Ghaferi AA: Bending the cost curve in the United States: the role of comparative effectiveness research. Crit Care 14:168, 2010
37. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, et al: Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526-529, 2000 (Pubitemid 32273628)
38. Giustina A, Bronstein MD, Casanueva FF, Chanson P, Ghigo E, Ho KK, et al: Current management practices for acromegaly: an international survey. Pituitary 14:125-133, 2011
39. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, et al: A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95:3141-3148, 2010
40. Holdaway IM, Bolland MJ, Gamble GD: A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159:89-95, 2008
41. Holdaway IM, Rajasoorya C: Epidemiology of acromegaly. Pituitary 2:29-41, 1999
42. Hua SC, Yan YH, Chang TC: Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. Eur J Endocrinol 155:831-837, 2006
43. Izawa M, Hayashi M, Nakaya K, Satoh H, Ochiai T, Hori T, et al: Gamma knife radiosurgery for pituitary adenomas. J Neurosurg 93 (Suppl 3):19-22, 2000 (Pubitemid 32799539)
44. Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD: Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin Endocrinol (Oxf) 67:310-315, 2007 (Pubitemid 47076313)
45. Jallad RS, Musolino NR, Salgado LR, Bronstein MD: Treatment of acromegaly: is there still a place for radiotherapy? Pituitary 10:53-59, 2007 (Pubitemid 46562808)
46. Jallad RS, Musolino NR, Salgado LR, Bronstein MD: Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol (Oxf) 63:168-175, 2005 (Pubitemid 41097985)
47. Jenkins PJ, Bates P, Carson MN, Stewart PM, Wass JA: Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab 91:1239-1245, 2006
48. Jenkins PJ, Emery M, Howling SJ, Evanson J, Besser GM, Monson JP: Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR. Horm Res 62:227-232, 2004 (Pubitemid 39551736)
49. Jezková J, Marek J, Hána V, Krsek M, Weiss V, Vladyka V, et al: Gamma knife radiosurgery for acromegaly-long-term experience. Clin Endocrinol (Oxf) 64:588-595, 2006
50. Karavitaki N, Turner HE, Adams CB, Cudlip S, Byrne JV, Fazal-Sanderson V, et al: Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol (Oxf) 68:970-975, 2008 (Pubitemid 351703951)
51. Katznelson L: Approach to the patient with persistent acromegaly after pituitary surgery. J Clin Endocrinol Metab 95:4114-4123, 2010
52. Kauppinen-Mäkelin R, Sane T, Sintonen H, Markkanen H, Välimäki MJ, Löyttyniemi E, et al: Quality of life in treated patients with acromegaly. J Clin Endocrinol Metab 91:3891-3896, 2006
53. Kreutzer J, Vance ML, Lopes MB, Laws ER Jr: Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 86:4072-4077, 2001 (Pubitemid 32848515)
54. Laws ER, Vance ML, Thapar K: Pituitary surgery for the management of acromegaly. Horm Res 53 (Suppl 3):71-75, 2000
55. Losa M, Gioia L, Picozzi P, Franzin A, Valle M, Giovanelli M, et al: The role of stereotactic radiotherapy in patients with growth hormone-secreting pituitary adenoma. J Clin Endocrinol Metab 93:2546-2552, 2008 (Pubitemid 352008518)
56. Marko NF, Weil RJ: An introduction to comparative effectiveness research. Neurosurgery 70:425-434, 2012
57. Matta MP, Couture E, Cazals L, Vezzosi D, Bennet A, Caron P: Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance. Eur J Endocrinol 158:305-310, 2008 (Pubitemid 351404993)
58. Melmed S: Acromegaly pathogenesis and treatment. J Clin Invest 119:3189-3202, 2009
59. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, et al: Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509-1517, 2009
60. Minniti G, Traish D, Ashley S, Gonsalves A, Brada M: Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab 90:800-804, 2005 (Pubitemid 40279200)
61. Moore DJ, Adi Y, Connock MJ, Bayliss S: Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation. BMC Endocr Disord 9:20, 2009
62. Murray RD, Melmed S: A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 93:2957-2968, 2008
63. Neggers SJ, de Herder WW, Janssen JA, Feelders RA, van der Lely AJ: Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol 160:529-533, 2009
64. Neggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA, Badia X, et al: Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 93:3853-3859, 2008
65. Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ: Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 92:4598-4601, 2007 (Pubitemid 350223432)
66. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, et al: Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 83:3034-3040, 1998 (Pubitemid 28500931)
67. Nicolucci A, Maione A, Franciosi M, Amoretti R, Busetto E, Capani F, et al: Quality of life and treatment satisfaction in adults with Type 1 diabetes: a comparison between continuous subcutaneous insulin infusion and multiple daily injections. Diabet Med 25:213-220, 2008 (Pubitemid 351293404)
68. Nomikos P, Buchfelder M, Fahlbusch R: The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure.' Eur J Endocrinol 152:379-387, 2005 (Pubitemid 40439490)
69. Pantanetti P, Sonino N, Arnaldi G, Boscaro M: Self image and quality of life in acromegaly. Pituitary 5:17-19, 2002 (Pubitemid 36267049)
70. Parkinson C, Burman P, Messig M, Trainer PJ: Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. J Clin Endocrinol Metab 92:190-195, 2007 (Pubitemid 46067530)
71. Pollock BE, Jacob JT, Brown PD, Nippoldt TB: Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission. J Neurosurg 106:833-838, 2007 (Pubitemid 46698669)
72. Powell JS, Wardlaw SL, Post KD, Freda PU: Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure. J Clin Endocrinol Metab 85:2068-2071, 2000 (Pubitemid 32269321)
73. Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM, Trainer PJ: Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. J Clin Endocrinol Metab 90:3337-3341, 2005 (Pubitemid 41014295)
74. Scheidegger U, Allemann S, Scheidegger K, Diem P: Continuous subcutaneous insulin infusion therapy: effects on quality of life. Swiss Med Wkly 137:476-482, 2007 (Pubitemid 47346424)
75. Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, et al: Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156:75-82, 2007 (Pubitemid 46553905)
76. Sheehan J, Pouratian N, Steiner L, Laws E, Vance M: Gamma Knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes. Clinical article. J Neurosurg 114:303-309 2011
77. Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon- Alonso A, Sheppard MC, et al: Mortality in patients with pituitary disease. Endocr Rev 31:301-342, 2010
78. Swearingen B, Barker FG II, Katznelson L, Biller BM, Grinspoon S, Klibanski A, et al: Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419-3426, 1998 (Pubitemid 28500866)
79. T'Sjoen G, Bex M, Maiter D, Velkeniers B, Abs R: Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian registry on acromegaly. Eur J Endocrinol 157:411-417, 2007
80. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman- Bonert V, van der Lely AJ, et al: Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171-1177, 2000 (Pubitemid 30211048)
81. Trepp R, Stettler C, Zwahlen M, Seiler R, Diem P, Christ ER: Treatment outcomes and mortality of 94 patients with acromegaly. Acta Neurochir (Wien) 147:243-251, 2005
82. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, et al: Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754-1759, 2001 (Pubitemid 33152999)
83. Verhelst JA, Pedroncelli AM, Abs R, Montini M, Vandeweghe MV, Albani G, et al: Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol 143: 577-584, 2000
84. Vik-Mo EO, Oksnes M, Pedersen PH, Wentzel-Larsen T, Rødahl E, Thorsen F, et al: Gamma knife stereotactic radiosurgery for acromegaly. Eur J Endocrinol 157:255-263, 2007 (Pubitemid 47603528)
85. Walgreens Health Initiatives. Volume 7, Number 3, March, 2003 (http://www.springsgov.com/units/empservices/Benefits-2003/Walgreens-News-Mar03. pdf) [Accessed May 1, 2012]
86. Webb SM, Badia X, Surinach NL, Spanish AcroQoL Study Group: Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. Eur J Endocrinol 155:269-277, 2006 (Pubitemid 44269443)
87. Wexler T, Gunnell L, Omer Z, Kuhlthau K, Beauregard C, Graham G, et al: Growth hormone deficiency is associated with decreased quality of life in patients with prior acromegaly. J Clin Endocrinol Metab 94:2471-2477, 2009
88. Wu YP, Graves MM, Roberts MC, Mitchell AC: Is insulin pump therapy better than injection for adolescents with diabetes? Diabetes Res Clin Pract 89:121-125, 2010
89. Zhang N, Pan L, Wang EM, Dai JZ, Wang BJ, Cai PW: Radiosurgery for growth hormone-producing pituitary adenomas. J Neurosurg 93 (Suppl 3):6-9, 2000 (Pubitemid 32799536)